CBD and blood thinners: a research-led safety overview
Bottom line — this is the most cautious page in our drug-interactions hub. Blood thinners and CBD interact through multiple liver-enzyme pathways (CYP2C9 for warfarin; CYP3A4 for Eliquis and Xarelto) and the P-glycoprotein transport system (Pradaxa). Bansal 2023 (n=18 RCT) showed CBD raised CYP2C and CYP3A substrate plasma exposure 56–207%. Cortopassi 2020 documented warfarin INR rising in a real patient after CBD initiation, requiring dose adjustment. Bleeding risk is the danger. Do not stop your anticoagulant. Do not start CBD without your prescriber's awareness. INR monitoring for warfarin; bleeding-symptom watch for all anticoagulants.
Key takeaways
- Warfarin (CYP2C9), apixaban and rivaroxaban (CYP3A4), edoxaban (partial CYP3A4) are all CBD-affected via CYP inhibition.
- Cortopassi 2020 documented INR rise after CBD initiation requiring warfarin dose adjustment.
- Dabigatran (Pradaxa) is not CYP-metabolized but is P-glycoprotein-affected; CBD modulates P-gp.
- Bleeding risk is the danger. INR monitoring for warfarin; bleeding-symptom watch for all DOACs.
- Do not stop your anticoagulant. Talk to your prescriber before adding CBD.
What the science says
Cortopassi 2020 — the case literature
Cortopassi 2020 is a published clinical case report: a warfarin-stabilized patient initiated CBD; INR rose; warfarin dose adjustment was required to restore the therapeutic INR window. This is real-world clinical evidence — not just mechanism-plausible reasoning. It's a single case, but it's been replicated mechanistically by Bansal 2023's RCT and by the broader CYP-overlap evidence.
The CYP2C9 mechanism (warfarin)
Warfarin is metabolized primarily by CYP2C9. CBD potently inhibits CYP2C9 (Yamaori 2011 in vitro; Bansal 2023 clinical). The result chain: warfarin plasma levels rise → anticoagulant effect strengthens → INR rises above therapeutic target → bleeding risk increases. The mechanism is unambiguous.
The CYP3A4 mechanism (apixaban, rivaroxaban, edoxaban)
Eliquis (apixaban) is primarily CYP3A4-metabolized. Xarelto (rivaroxaban) similarly. Edoxaban is partially CYP3A4. CBD inhibits CYP3A4 — Bansal documented 56–207% substrate exposure rise across the panel. The danger with DOACs: there is no routine monitoring equivalent to INR, so CBD-induced exposure rises can go unnoticed until bleeding occurs. Nachnani 2024's systematic review documented anticoagulant interactions across 889 patients.
The P-glycoprotein mechanism (dabigatran)
Pradaxa (dabigatran) is not CYP-metabolized but is a P-glycoprotein (P-gp) substrate. CBD modulates P-gp transport — less directly than CYP, but documented. Pradaxa exposure could plausibly rise with CBD, though the case literature is thinner than for warfarin.
The compounding factor: NSAIDs
Many readers landing here are also on NSAIDs (celebrex, meloxicam, ibuprofen). NSAIDs themselves increase GI bleeding risk; adding CBD's CYP-pathway effects to an NSAID plus anticoagulant stack triples up the bleeding-risk variables. Stöllberger 2023's 403-drug overlap review explicitly flags NSAIDs and anticoagulants as a high-attention combination with CBD.
The mechanism
Four pathways converge on the same outcome:
| Anticoagulant | Pathway | CBD effect |
|---|---|---|
| Warfarin | CYP2C9 primary | CBD inhibits → warfarin plasma rises → INR rises |
| Apixaban (Eliquis) | CYP3A4 primary | CBD inhibits → plasma exposure rises (unmonitored) |
| Rivaroxaban (Xarelto) | CYP3A4 primary | CBD inhibits → plasma exposure rises (unmonitored) |
| Edoxaban (Savaysa) | Partial CYP3A4 + P-gp | Both pathways CBD-affected |
| Dabigatran (Pradaxa) | P-glycoprotein substrate | CBD modulates P-gp; mechanism less direct |
All five pathways converge on a single clinical outcome: plasma anticoagulant levels rise above the prescribed-dose target, and bleeding risk increases. See the CYP450 mechanism explainer for the foundational pharmacology.
What this means for you
- Talk to your prescriber BEFORE adding CBD. Not after. Bleeding events from unmonitored interactions can be life-threatening.
- For warfarin specifically: schedule an INR check shortly after starting CBD. Your prescriber may want INR within 1–2 weeks of CBD initiation, then again 4–6 weeks later as anticoagulant management adjusts.
- For DOACs (Eliquis, Xarelto, Savaysa, Pradaxa): no routine monitoring exists, so bleeding-symptom watch is the only signal. Watch for unusual bruising, blood in urine or stool, prolonged bleeding from minor cuts, gum bleeding, severe headache, weakness on one side, vision changes. Any of these = call your prescriber immediately.
- Format choice matters most for this drug class. Topical CBD (NANO roll-on) has minimal systemic absorption — the lowest-CYP-impact format. If your prescriber will not allow oral CBD with your anticoagulant, topical is a meaningful lower-risk option for localized joint pain.
- Do not stack CBD plus anticoagulant plus NSAID without explicit prescriber sign-off. That combination compounds bleeding risk on multiple axes.
- Don't switch anticoagulants based on this page. If you're on warfarin and tempted to switch to a DOAC because warfarin has a documented CBD interaction — don't. The DOACs have CBD interactions too; they're just less monitored. Anticoagulant choice is between you and your prescriber based on your underlying condition.
- CBD does NOT replace your anticoagulant. Reclaim does not recommend stopping anticoagulation under any circumstances.
Anticoagulant brand-name reference
| Brand | Generic | Class | CBD-interaction pathway |
|---|---|---|---|
| Coumadin / Jantoven | Warfarin | Vitamin K antagonist | CYP2C9 (severe; INR-monitorable) |
| Eliquis | Apixaban | Direct factor Xa inhibitor | CYP3A4 (severe; no routine monitoring) |
| Xarelto | Rivaroxaban | Direct factor Xa inhibitor | CYP3A4 (severe) |
| Savaysa / Lixiana | Edoxaban | Direct factor Xa inhibitor | Partial CYP3A4 + P-gp (moderate-severe) |
| Pradaxa | Dabigatran | Direct thrombin inhibitor | P-glycoprotein (moderate; mechanism less direct) |
| Bayer aspirin (low-dose) | Aspirin | Antiplatelet | Minor CYP2C9 + bleeding-additive |
| Plavix | Clopidogrel | Antiplatelet | CYP2C19 (significant — CBD inhibits) |
| Brilinta | Ticagrelor | Antiplatelet | CYP3A4 (significant) |
| Effient | Prasugrel | Antiplatelet | Mostly esterase + CYP3A4/2B6 (moderate) |
Frequently asked questions
Can I take CBD if I'm on warfarin?
Talk to your prescriber BEFORE adding CBD. Cortopassi 2020 documented a real clinical case: warfarin INR rose after CBD initiation, requiring dose adjustment. The mechanism (CYP2C9 inhibition) is well-established (Yamaori 2011, Bansal 2023). If your prescriber agrees to a CBD trial, they'll likely want an INR check within 1–2 weeks of starting and again 4–6 weeks later. Reclaim does not recommend stopping warfarin under any circumstances.
What about Eliquis (apixaban) or Xarelto (rivaroxaban) — do they interact too?
Yes. Apixaban and rivaroxaban are CYP3A4-metabolized; CBD inhibits CYP3A4 (Bansal 2023 showed 56–207% rise in CYP3A substrate exposure). The danger with DOACs is there's no routine monitoring — no INR equivalent — so a CBD-induced exposure rise can go unnoticed until bleeding occurs. Talk to your prescriber. Watch for bleeding symptoms (unusual bruising, blood in urine or stool, gum bleeding, severe headache).
Is Pradaxa (dabigatran) different?
Yes. Pradaxa is not CYP-metabolized; it's a P-glycoprotein substrate. CBD modulates P-glycoprotein transport, so Pradaxa exposure could plausibly rise — but the mechanism is less direct than CYP-mediated interactions, and there's less case literature. Don't take this as "safer with CBD" — talk to your prescriber. Bleeding-symptom watch still applies.
Can I take topical CBD safely on a blood thinner?
Topical CBD has minimal systemic absorption. From a CYP-interaction standpoint, topical is the lowest-risk format. Some patients on anticoagulation use topical CBD for joint pain with prescriber agreement. But: prescriber sign-off still matters because (a) any oral or transdermal absorption raises the question, and (b) some topicals are absorbed more than others depending on skin condition.
Should I switch anticoagulants because of CBD?
No. Anticoagulant choice (warfarin vs DOAC vs antiplatelet) is between you and your prescriber based on your underlying condition (atrial fibrillation, mechanical valve, DVT history). All anticoagulants have CBD-interaction pathways — warfarin via CYP2C9, DOACs via CYP3A4 or P-gp. Switching anticoagulants doesn't eliminate the interaction; it just changes which pathway. The stable answer is: stay on the anticoagulant your prescriber chose, and talk to them about CBD.
Can I take low-dose aspirin with CBD?
Talk to your prescriber. Low-dose aspirin (81mg) is mostly cleared by esterase hydrolysis with minor CYP2C9 contribution; the direct CBD interaction is smaller than for warfarin. But aspirin is an antiplatelet — it adds bleeding risk additively to anticoagulants and to CBD's CYP effects on other CYP-metabolized drugs in your stack. The combination of aspirin plus CBD plus an NSAID compounds bleeding risk meaningfully even without a sharp single CYP interaction.
References
- Cortopassi J. (2020). Warfarin dose adjustment required after cannabidiol initiation. PMID 33016308
- Bansal S et al. (2023). Cannabidiol effects on the pharmacokinetics of substrates of cytochrome P450 enzymes. PMID 37313955
- Yamaori S et al. (2011). Cannabidiol is a potent inhibitor of cytochrome P450 enzymes. PMID 21356216
- Doohan PT et al. (2021). Cannabinoid interactions with cytochrome P450 drug metabolism. PMID 34181150
- Stöllberger C, Finsterer J. (2023). Interactions between cannabidiol and commonly used prescription drugs. PMID 37541924
- Nachnani R et al. (2024). Cannabidiol-prescription drug interactions: a systematic review. PMID 38868665
Related reading
Some related pages are still being written.